Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2022-10-07

FDA Approved: TIVICAY PD — Supplemental Application (ViiV Healthcare Company)

View source ↗

Summary

The FDA approved a supplemental application for Tivicay PD (dolutegravir sodium) submitted by ViiV Healthcare Company.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TIVICAY PD (dolutegravir sodium)

Snippet

SUPPL AP for TIVICAY PD (DOLUTEGRAVIR SODIUM)